Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 1/20 | 0.38 |
| ▸ | KIF11 | P52732 | 2/20 | 0.34 |
| ▸ | PDE2A | O00408 | 2/20 | 0.33 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12829127 | 0.87 | KIF11 (0.35) | GPR3KIF11CYP11B1CYP11B2 | |
| SCHEMBL18265626 | 0.87 | KIF11 (0.35) | GPR3KIF11CYP11B1CYP11B2 | |
| SCHEMBL12829126 | 0.87 | GPR3 (0.38) | GPR3KIF11CYP11B1CYP11B2AR | |
| SCHEMBL15773593 | 0.84 | CYP11B1 (0.35) | GPR3KIF11CYP11B1CYP11B2AR | |
| SCHEMBL18887806 | 0.82 | PDE2A (0.32) | PDE2ACYP11B1CYP11B2 | |
| SCHEMBL15318779 | 0.82 | KIF11 (0.33) | GPR3KIF11CYP11B1CYP11B2 | |
| SCHEMBL14240857 | 0.81 | KIF11 (0.33) | GPR3KIF11 | |
| SCHEMBL6470423 | 0.81 | KIF11 (0.42) | GPR3KIF11CYP11B1CYP11B2AR | |
| SCHEMBL91865 | 0.81 | GPR3 (0.37) | GPR3 | |
| SCHEMBL12829125 | 0.81 | GPR3 (0.36) | GPR3KIF11PDE2AMRGPRX4AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9822305-B2 | Liquid crystal medium and liquid crystal display | MERCK PATENT GMBH (DE) | 2017-11-21 | — | — | US | disclosed |
| US-9809749-B2 | Mesogenic compound, liquid-crystal medium and liquid crystal display | MERCK PATENT GMBH (DE) | 2017-11-07 | — | — | US | disclosed |
| US-9593279-B2 | Liquid-crystalline medium and high-frequency components comprising same | MERCK PATENT GMBH (DE) | 2017-03-14 | — | — | US | disclosed |
| US-20160115388-A1 | MESOGENIC COMPOUND, LIQUID-CRYSTAL MEDIUM AND LIQUID CRYSTAL DISPLAY | MERCK PATENT GMBH (DE) | 2016-04-28 | — | — | US | disclosed |
| US-7914859-B2 | Light modulation media, use in particular for electrooptic displays which are operated at a temperature at which the mesogenic modulation media are in an optically isotropic phase, preferably in a blue phase; reduced operating voltage, reduced temperature dependency of operating voltage, reliability | MERCK PATENT GMBH (DE) | 2011-03-29 | — | — | US | disclosed |
| EP-1739151-B1 | Mesogenic compounds, liquid crystal medium and liquid display | MERCK PATENT GMBH (DE) | 2010-09-15 | — | — | EP | disclosed |
| EP-1816180-B1 | Mesogenic compounds, liquid crystal medium, and liquid crystal display | MERCK PATENT GMBH (DE) | 2008-10-29 | — | — | EP | disclosed |
| EP-1690917-B1 | Mesogenic compounds, liquid crystal medium and liquid crystal display | MERCK PATENT GMBH (DE) | 2008-10-08 | — | — | EP | disclosed |
| US-20080116419-A1 | Mesogenic Compounds, Liquid Crystal Medium and Liquid Crystal Display | MERCK PATENT GMBH (DE) | 2008-05-22 | — | — | US | disclosed |
| EP-1690915-B1 | Mesogenic compounds, liquid crystal medium and liquid crystal display | MERCK PATENT GMBH (DE) | 2008-03-26 | — | — | EP | disclosed |
| EP-1690916-B1 | Mesogenic compounds, liquid crystal medium and liquid crystal display | MERCK PATENT GMBH (DE) | 2008-03-12 | — | — | EP | disclosed |
| EP-1816180-A1 | Mesogenic compounds, liquid crystal medium, and liquid crystal display | Merck Patent GmbH (DE) | 2007-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160115388-A1 | MESOGENIC COMPOUND, LIQUID-CRYSTAL MEDIUM AND LIQUID CRYSTAL DISPLAY | BMP2, IK, EML4 | GPR3 3750/4885KIF11 119/4885PDE2A 2495/4885 |
| US-20080116419-A1 | Mesogenic Compounds, Liquid Crystal Medium and Liquid Crystal Display | CRY1, CRY2, IK | GPR3 1998/4885KIF11 330/4885PDE2A 1930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.